Drug Development
Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Apellis Pharmaceuticals reported topline results from its Phase III DERBY and OAKS clinical trials for geographic atrophy secondary to age-related macular degeneration.
A recently published study points to a previous SARS infection—plus vaccination—as the key to a robust immunity against SARS-CoV-2.
This week, the mRNA leader followed up its announcement of a collaboration with the Institute for Life Changing Medicines (ILCM), with an update on several programs advancing in its pipeline.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Durham, N.C.-based Precision BioSciences announced a license and collaboration deal with Philadelphia-based iECURE and described its clinical development plans.
The FDA stated that it could not determine if the use of lenzilumab in COVID patients outweighs the known and potential safety risks.
Paris-based Sanofi announced its Phase III PEGASUS clinical trial of rilzabrutinib for pemphigus failed to hit primary or key secondary endpoints.
Scientists from different agencies and research facilities have turned to laboratory manufactured human mini-brains to study the onset and progression of Parkinson’s disease.
Norovirus vaccine is being developed at a rapid pace. HilleVax invests $135 million to rapidly progress the development. Here’s more about the vaccine.
Heading into fall, with the COVID-19 pandemic surging again and researchers tracking new variants, there’s plenty of news. Here’s a look.